Lung Cancer

Current Projects
Liron Bar-Peled, PhD

Dr. Bar-Peled studies how cancer cells adapt to stress environments, focusing on oxidative stress.  His research focuses on understanding how cells sense and respond to specific changes in their environment by activating singling pathways that lead to uncontrolled growth.  He recently studied a particular pathway in non-small cell lung cancer and identified a “druggable” protein that could be targeted with small molecules and disrupt this uncontrolled growth. He plans to pursue this specific target and use the same strategy for identifying druggable pathways in other cancers that currently lack effective therapies.

Project title: "Identification of cysteine liabilities in NRF2-driven cancers"
Institution: The Scripps Research Institute
Award Program: Dale Frey Scientist
Cancer Type: Lung, All Cancers
Research Area: Chemical Biology
Angela N. Brooks, PhD

Dr. Brooks is analyzing cancer genome sequence data to identify DNA mutations that affect RNA splicing, a form of gene processing and regulation. By characterizing these mutations, her work will provide further understanding of the role of splicing alterations in cancer as well as insight into the functional consequences of cancer mutations.


Project title: "Characterizing somatic mutations that affect mRNA splicing in cancer"
Institution: University of California, Santa Cruz
Award Program: Dale Frey Scientist
Cancer Type: Blood, Lung, All Cancers
Research Area: Genomics
Sidi Chen, PhD

Dr. Chen aims to understand the relationship between small RNAs and cancer.  Small RNAs are important regulators of genetic networks inside the cell; perturbation of these networks can lead to malignant cell growth.  His goal is to develop anti-cancer drugs and therapies by targeting the process of small RNA production.

Project title: "Investigation of Dicer as a novel therapeutic route towards the inhibition of tumorigenesis and neoplastic growth"
Institution: Yale University
Award Program: Dale Frey Scientist
Cancer Type: Lung, Sarcoma
Research Area: Cancer Genetics
Trudy G. Oliver, PhD

Many cancers initially respond to therapy. However, cancers often acquire resistance and stop responding to further treatment. Small cell lung cancer (SCLC) is an example of a cancer that is highly sensitive to initial treatment, but quickly acquires a vicious resistance resulting in a five-year patient survival rate of less than 4%. In order to combat drug resistance and improve the quality of life for patients with SCLC, it is important to understand the key genetic changes and cellular pathways that drive resistance.

Dr. Oliver will use the most innovative next-generation sequencing technologies to comprehensively identify critical genetic changes associated with resistance. These findings will be essential for understanding how lung cancer, and potentially other types of cancer, evades chemotherapy. In addition, this work will identify novel pathways that could be targeted to re-establish drug sensitivity and thereby provide new treatment options for patients with drug-resistant disease.  


Project title: "Mechanisms of drug resistance in small cell lung cancer"
Institution: University of Utah
Award Program: Innovator
Cancer Type: Lung
Research Area: Chemoresistance
Victoria E.H. Wang, MD, PhD

Dr. Wang seeks to understand the mechanisms by which tumor cells become resistant to drug therapy and spread to distant organs. She is utilizing functional genomics tools to identify novel pathways modulating these processes in the hope of developing new therapies to augment treatment response in cancer patients. 

Project title: "The role of the c-Met/Hepatocyte growth factor (HGF) pathway in drug resistance and tumor metastasis"
Institution: University of California, San Francisco
Award Program: Fellow
Sponsor(s) / Mentor(s): Frank McCormick, PhD
Cancer Type: Other Cancer, Lung, All Cancers
Research Area: Chemoresistance
  • You can support our innovative researchers.